About the USAGE Survey
The USAGE survey, which is sponsored by a partnership between Kowa Pharmaceuticals America, Inc. and the National Lipid Association (NLA)., unveils a deeper understanding of cholesterol management, including the importance of doctor – patient communication, the impact of side effects, the potential for drug-drug interactions and awareness of personal lipid levels. Previous studies indicate that as many as 50% of statin users discontinue medication within months of the initial prescription and up to 25% stop after one month—quite possibly after filling only a single order at the pharmacy. Nearly 75% of new users discontinue their therapy by the end of the first year.
The USAGE survey has been particularly valuable in uncovering information that may help provide greater insight into statin non-adherence—one of the biggest barriers to effective treatment today.
Doctors write more than 200 million prescriptions for statins in the U.S. each year. While statins are highly successful in reducing cholesterol levels, only one-third of people with high cholesterol have their cholesterol under control. This is a major public health concern, as the direct medical costs for cardiovascular disease (CVD) in the U.S. are expected to triple from $273 billion currently to $818 billion in 2030.
Overall, 61% of USAGE survey respondents were female and 39% were male. Respondents were an average of 61 years old and had an average household income of $63,000. The survey examined key patient concerns, including dosing and both short- and long-term side effects, that may provide insights about patient motivations underlying statin non-adherence. The USAGE survey findings about the behaviors of current and former statin users may help to enhance communication between physicians and patients and facilitate a collaborative discussion to effectively select and manage statin therapy.
For a more extensive summary of these results, see Key Findings and Implications.